Navigation Links
ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that clinical findings for three different TAP compounds for the treatment of solid tumors are to be reported at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting to take place June 1-5, 2007 in Chicago, IL.

Trastuzumab-DM1 (abstract #1042)

"A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)."

-- Saturday, June 2, 2:00-6:00 pm: Breast Cancer - Metastatic General Poster Session (poster #G4).

-- Trastuzumab-DM1 is in development by Genentech.

HuC242-DM4 (abstract #3062)

"A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors."

-- Sunday, June 3, 8:00 am-12:00 noon: Developmental Therapeutics: Immunotherapy General Poster Session (poster #F14).

-- HuC242-DM4 is wholly owned by ImmunoGen.

HuN901-DM1 (abstract #18084)

"Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma."

-- To be published as abstract in the Journal of Clinical Oncology.

-- HuN901-DM1 is wholly owned by ImmunoGen.

About ImmunoGen's TAP Technology

ImmunoGen created its TAP technology to enhance the anticancer activity of tumor-targeting antibodies while maintaining a favorable tolerability profile. The Company attaches to an antibody one of ImmunoGen's proprietary cell-killing agents. The antibody serves to deliver the agent specifically to cancer cells and the agent serves to kill the cancer cells. The agent is attached using one of the Company's "linkers." ImmunoGen has developed alte rnative cell-killing agents and linkers so the best product design can be achieved for each antibody and its target. ImmunoGen uses its cell-killing agents with its wholly-owned antibodies to create its own anticancer compounds, and also outlicenses its technology for use by other companies with their proprietary antibodies. Companies licensing the right to develop anticancer compounds to specific targets using ImmunoGen's TAP technology include Biogen Idec, Biotest AG, Centocor (Johnson & Johnson), Genentech, and sanofi-aventis.

Four TAP compounds are already in clinical testing - huN901-DM1 and huC242-DM4, in development by ImmunoGen, trastuzumab-DM1, in development by Genentech, and AVE9633, in development by sanofi-aventis. ImmunoGen expects its collaborators to advance two additional TAP compounds into clinical testing in 2007.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development.

This press release includes forward-looking statements based on management's current expectations. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause the Company's actual results to differ materially from those discussed or implied in the forward-looking statements and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the outcome of the Company's research and clinical development processes; the outcome of the Company's collaboration partners' research and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense and results of preclinical studies and clinical trials; the Company's dependence on collaborative partners; and other factors more fully described in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2006 and other reports filed with the Securities and Exchange Commission.


ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations
and Corporate Communications
Kathryn Morris, 845-635-9828


Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the Global Cell Surface Testing Market: ... report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... Research and Markets ( ) has ... Market by Type (Dressings, Therapy Devices, Active Wound Care), ... Facility), and Geography - Global Forecast to 2020" ... --> The purpose of this report ... the global advanced wound care market. It involves deep ...
(Date:11/26/2015)... 26, 2015 ) ... Administration of High Viscosity Drugs" report to ... announced the addition of the "Self Administration ... offering. --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... According to an article published November 13th on, much ... revolved around the fact that proper dental care, both at-home and in the dental ... periodontal disease (more commonly referred to as gum disease) and diabetes. According to Dr. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... how filthy the toilets were," said an inventor from Hillside, N.J. "Many people ... improved seat cover so that individuals will always be protected from germs." , ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion ... Cut Pro X. With ProSidebar: Fasion, video editors can easily add an informative ... a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, bars, and ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official ... independent group of Microsoft Dynamics SL software users, partners, industry experts and representatives. ...
Breaking Medicine News(10 mins):